154 related articles for article (PubMed ID: 31121994)
1. Cardiovascular Safety and Possible Benefit of a 5-Alpha Reductase Inhibitor among Benign Prostatic Hyperplasia Patients, A Nationally Representative Cohort of Korean Men.
Chang J; Choi S; Kim K; Park SM
J Clin Med; 2019 May; 8(5):. PubMed ID: 31121994
[TBL] [Abstract][Full Text] [Related]
2. Impact of 5α-reductase inhibitor and α-blocker therapy for benign prostatic hyperplasia on prostate cancer incidence and mortality.
Van Rompay MI; Curtis Nickel J; Ranganathan G; Kantoff PW; Solomon KR; Lund JL; McKinlay JB
BJU Int; 2019 Mar; 123(3):511-518. PubMed ID: 30216624
[TBL] [Abstract][Full Text] [Related]
3. Five-alpha reductase inhibitors and risk of prostate cancer among men with benign prostatic hyperplasia: A historical cohort study using primary care data.
Thakrar DB; Douglas IJ; Smeeth L; Bhaskaran K
Wellcome Open Res; 2023; 8():295. PubMed ID: 38774490
[No Abstract] [Full Text] [Related]
4. The Cardiovascular Safety of Five-Alpha-Reductase Inhibitors Among Men with Benign Prostatic Hyperplasia: A Population-Based Cohort Study.
Ayele HT; Reynier P; Azoulay L; Platt RW; Benayoun S; Filion KB
Am J Med; 2023 Oct; 136(10):1000-1010.e7. PubMed ID: 37481022
[TBL] [Abstract][Full Text] [Related]
5. The Risk of Venous Thromboembolism (VTE) in Men with Benign Prostatic Hyperplasia Treated with 5-Alpha Reductase Inhibitors (5ARIs).
Ayodele O; Cabral HJ; McManus D; Jick S
Clin Epidemiol; 2021; 13():661-673. PubMed ID: 34377032
[TBL] [Abstract][Full Text] [Related]
6. 5-alpha-reductase inhibitors and the risk of diabetes mellitus: A nationwide population-based study.
Lee SS; Yang YW; Tsai TH; Kuo YH; Chuang HY; Lee CC; Hsieh TF
Prostate; 2016 Jan; 76(1):41-7. PubMed ID: 26390988
[TBL] [Abstract][Full Text] [Related]
7. 5α-Reductase inhibitors and risk of high-grade or lethal prostate cancer.
Preston MA; Wilson KM; Markt SC; Ge R; Morash C; Stampfer MJ; Loda M; Giovannucci E; Mucci LA; Olumi AF
JAMA Intern Med; 2014 Aug; 174(8):1301-7. PubMed ID: 24887392
[TBL] [Abstract][Full Text] [Related]
8. Drug adherence and clinical outcomes for patients under pharmacological therapy for lower urinary tract symptoms related to benign prostatic hyperplasia: population-based cohort study.
Cindolo L; Pirozzi L; Fanizza C; Romero M; Tubaro A; Autorino R; De Nunzio C; Schips L
Eur Urol; 2015 Sep; 68(3):418-25. PubMed ID: 25465970
[TBL] [Abstract][Full Text] [Related]
9. Depression risk associated with the use of 5α-reductase inhibitors versus α-blockers: A retrospective cohort study in South Korea.
Yeon B; Suh AY; Choi E; Kim B; Noh E; Chung SY; Han SY
PLoS One; 2022; 17(3):e0265169. PubMed ID: 35294468
[TBL] [Abstract][Full Text] [Related]
10. The Use of 5-Alpha Reductase Inhibitors to Manage Benign Prostatic Hyperplasia and the Risk of All-cause Mortality.
Wallner LP; DiBello JR; Li BH; Van Den Eeden SK; Weinmann S; Ritzwoller DP; Abell JE; D'Agostino R; Loo RK; Aaronson DS; Horwitz RI; Jacobsen SJ
Urology; 2018 Sep; 119():70-78. PubMed ID: 29906480
[TBL] [Abstract][Full Text] [Related]
11. Efficacy and safety of 5 alpha-reductase inhibitor monotherapy in patients with benign prostatic hyperplasia: A meta-analysis.
Kim JH; Baek MJ; Sun HY; Lee B; Li S; Khandwala Y; Del Giudice F; Chung BI
PLoS One; 2018; 13(10):e0203479. PubMed ID: 30281615
[TBL] [Abstract][Full Text] [Related]
12. Risk Analysis of Prostate Cancer Development Following Five-alpha Reductase Inhibitor Treatment for Benign Prostate Hyperplasia.
Chang LW; Wang SS; Yang CK; Lu K; Chen CS; Cheng CL; Hung SC; Chiu KY; Hsu CY; Li JR
Anticancer Res; 2023 Jan; 43(1):485-491. PubMed ID: 36585197
[TBL] [Abstract][Full Text] [Related]
13. Risk of rhabdomyolysis from 5-α reductase inhibitors.
Welk B; McArthur E; Ordon M; Dirk J; Dixon S; Garg AX
Pharmacoepidemiol Drug Saf; 2018 Mar; 27(3):351-355. PubMed ID: 29368380
[TBL] [Abstract][Full Text] [Related]
14. Hyperlipidemia is associated with an increased risk of clinical benign prostatic hyperplasia.
Shih HJ; Huang CJ; Lin JA; Kao MC; Fan YC; Tsai PS
Prostate; 2018 Feb; 78(2):113-120. PubMed ID: 29119583
[TBL] [Abstract][Full Text] [Related]
15. 5α-reductase inhibitors and the risk of bladder cancer in a large, population-based cohort.
Dekalo S; McArthur E; Campbell J; Ordon M; Power N; Welk B
Urol Oncol; 2023 Jan; 41(1):50.e11-50.e17. PubMed ID: 36319553
[TBL] [Abstract][Full Text] [Related]
16. Early symptom improvement and discontinuation of 5-α-reductase inhibitor (5ARI) therapy in patients with benign prostatic hyperplasia (BPH).
Kruep EJ; Phillips E; Hogue S; Eaddy M
Ann Pharmacother; 2014 Mar; 48(3):343-8. PubMed ID: 24311727
[TBL] [Abstract][Full Text] [Related]
17. Risk of gynecomastia and breast cancer associated with the use of 5-alpha reductase inhibitors for benign prostatic hyperplasia.
Hagberg KW; Divan HA; Fang SC; Nickel JC; Jick SS
Clin Epidemiol; 2017; 9():83-91. PubMed ID: 28228662
[TBL] [Abstract][Full Text] [Related]
18. Impact of delaying 5-alpha reductase inhibitor therapy in men on alpha-blocker therapy to treat BPH: assessment of acute urinary retention and prostate-related surgery.
Naslund M; Eaddy MT; Hogue SL; Kruep EJ; Shah MB
Curr Med Res Opin; 2009 Nov; 25(11):2663-9. PubMed ID: 19757985
[TBL] [Abstract][Full Text] [Related]
19. Use of 5-alpha-reductase inhibitors did not increase the risk of cardiovascular diseases in patients with benign prostate hyperplasia: a five-year follow-up study.
Hsieh TF; Yang YW; Lee SS; Lin TH; Liu HH; Tsai TH; Chen CC; Huang YS; Lee CC
PLoS One; 2015; 10(3):e0119694. PubMed ID: 25803433
[TBL] [Abstract][Full Text] [Related]
20. Establishing the clinical and economic benefits of adherence to 5-alpha reductase inhibitors in benign prostatic hyperplasia: an assessment of Medicare and Medicaid patients.
Eaddy M; Kruep E; Lunacsek O; Goodwin B
Expert Opin Pharmacother; 2012 Dec; 13(18):2593-600. PubMed ID: 23163741
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]